Sevelamer, a Phosphate-Binding Polymer, is a Non-Absorbed Compound
- 1 January 2002
- journal article
- clinical trial
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 41 (7) , 517-523
- https://doi.org/10.2165/00003088-200241070-00005
Abstract
To examine the absorption, distribution and excretion of sevelamer hydrochloride in rats and humans. Twelve male Sprague-Dawley rats were used in the animal study, and twenty human volunteers participated in the clinical trial. In the animal study, six rats received a single oral dose of [3H]sevelamer and six rats were pretreated with unlabelled sevelamer in the diet for 28 days followed by a single dose of [3H] sevelamer on day 29. Total urine and faeces were collected at intervals up to 72 hours post dose, and tissues were obtained at the time of sacrifice. In the clinical trial, subjects received a single oral dose of [14C]sevelamer following 28 days of pretreatment with unlabelled sevelamer. Blood, urine and faeces samples were collected at intervals up to 96 hours. In the rat study, no significant urinary excretion of radioactivity was observed. The average recovery of radioactivity in the faeces was 98% in the single-dose group and greater than 100% in the group pretreated with unlabelled sevelamer for 28 days. A total of less than 0.1% of the dose was found in the tissues. In the human study, no detectable amount of 14C was found in the blood of any subject at any time. The majority of subjects had no detectable amounts of 14C recovered in the urine. In subjects where 14C was recovered in the urine, less than 0.02% was detected, a level equivalent to the free 14C detected in the [14C]sevelamer preparation. On average, greater than 99% of the administered dose was recovered in the faeces of the subjects. These studies demonstrate that sevelamer is a non-absorbed compound.Keywords
This publication has 16 references indexed in Scilit:
- Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients*Nephrology Dialysis Transplantation, 1999
- RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormoneKidney International, 1999
- Are we mismanaging calcium and phosphate metabolism in renal failure?American Journal of Kidney Diseases, 1997
- Aluminum Toxicity in Patients with Chronic Renal FailureTherapeutic Drug Monitoring, 1993
- Aluminum Accumulation during Treatment with Aluminum Hydroxide and Dialysis in Children and Young Adults with Chronic Renal DiseaseNew England Journal of Medicine, 1991
- Calcium Carbonate as a Phosphate Binder in Patients with Chronic Renal Failure Undergoing DialysisNew England Journal of Medicine, 1986
- Excretion and retention of low or moderate levels of aluminium by human subjectsFood and Chemical Toxicology, 1983
- Hemodialysis encephalopathy with osteomalacic fractures and muscle weaknessKidney International, 1980
- FRACTURING DIALYSIS OSTEODYSTROPHY AND DIALYSIS ENCEPHALOPATHY: An Epidemiological SurveyPublished by Elsevier ,1979
- Preparation of [14c]colestipol hydrochloride and its disposition in the human, dog and ratAtherosclerosis, 1978